Join Growin Stock Community!

Innate pharma s.a.IPHA.US Overview

US StockHealthcare
(No presentation for IPHA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IPHA AI Insights

IPHA Overall Performance

IPHA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IPHA Recent Performance

-0.58%

Innate pharma s.a.

0.05%

Avg of Sector

-0.31%

S&P500

IPHA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IPHA Key Information

IPHA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IPHA Profile

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Price of IPHA

IPHA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IPHA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.72
PB Ratio
26.45
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
266.59%
Net Margin
-896.63%
Revenue Growth (YoY)
-84.80%
Profit Growth (YoY)
168.95%
3-Year Revenue Growth
-50.98%
3-Year Profit Growth
186.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.72
PB Ratio
26.45
Price-to-FCF
-
Gross Margin
266.59%
Net Margin
-896.63%
Revenue Growth (YoY)
-84.80%
Profit Growth (YoY)
168.95%
3-Year Revenue Growth
-50.98%
3-Year Profit Growth
186.82%

  • When is IPHA's latest earnings report released?

    The most recent financial report for Innate pharma s.a. (IPHA) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IPHA's short-term business performance and financial health. For the latest updates on IPHA's earnings releases, visit this page regularly.

  • What is the operating profit of IPHA?

    According to the latest financial report, Innate pharma s.a. (IPHA) reported an Operating Profit of -25.43M with an Operating Margin of -523.19% this period, representing a growth of 3.37% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IPHA's revenue growth?

    In the latest financial report, Innate pharma s.a. (IPHA) announced revenue of 4.86M, with a Year-Over-Year growth rate of -60.63%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IPHA have?

    As of the end of the reporting period, Innate pharma s.a. (IPHA) had total debt of 27.03M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IPHA have?

    At the end of the period, Innate pharma s.a. (IPHA) held Total Cash and Cash Equivalents of 53.7M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IPHA's EPS continuing to grow?

    According to the past four quarterly reports, Innate pharma s.a. (IPHA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IPHA?

    Innate pharma s.a. (IPHA)'s Free Cash Flow (FCF) for the period is -31.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,234.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.